These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 28614091)

  • 21. Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study.
    Won CH; Kim HK; Kim BJ; Kang H; Hong JP; Lee SY; Kim CS
    Int J Dermatol; 2015 Feb; 54(2):227-34. PubMed ID: 25311357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Randomized, Double-Blind Trial to Investigate the Equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for Glabellar Frown Lines.
    Kane MA; Gold MH; Coleman WP; Jones DH; Tanghetti EA; Alster TS; Rohrer TE; Burgess CM; Shamban AT; Finn E
    Dermatol Surg; 2015 Nov; 41(11):1310-9. PubMed ID: 26509943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety.
    Brandt F; Swanson N; Baumann L; Huber B
    Dermatol Surg; 2009 Dec; 35(12):1893-901. PubMed ID: 19549186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progressive Improvement in Static Glabellar Lines After Repeated Treatment With DaxibotulinumtoxinA for Injection.
    Glogau R; Kontis TC; Liu Y; Gallagher CJ
    Dermatol Surg; 2021 Dec; 47(12):1579-1584. PubMed ID: 34417396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of botulinum toxin dose with neurophysiological parameters of efficacy and safety in the glabellar muscles: a double-blind, placebo-controlled, randomized study.
    Alimohammadi M; Andersson M; Punga AR
    Acta Derm Venereol; 2014 Jan; 94(1):32-7. PubMed ID: 23975053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. OnabotulinumtoxinA for Treatment of Forehead and Glabellar Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Double-Blind Study.
    Ogilvie P; Rivkin AZ; Dayan S; Yoelin SG; Weichman BM; Garcia JK
    Dermatol Surg; 2019 May; 45(5):689-699. PubMed ID: 31034447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines: A Focus on Safety From the SAKURA 3 Study.
    Green JB; Mariwalla K; Coleman K; Ablon G; Weinkle SH; Gallagher CJ; Vitarella D; Rubio RG
    Dermatol Surg; 2021 Jan; 47(1):42-46. PubMed ID: 32773447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials.
    Gallagher CJ; Bowsher RR; Clancy A; Dover JS; Humphrey S; Liu Y; Prawdzik G
    Toxins (Basel); 2023 Jan; 15(1):. PubMed ID: 36668880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A four-month randomized, double-blind evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VI.
    Grimes PE; Shabazz D
    Dermatol Surg; 2009 Mar; 35(3):429-35; discussion 435-6. PubMed ID: 19250310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females.
    Carruthers A; Carruthers J; Said S
    Dermatol Surg; 2005 Apr; 31(4):414-22; discussion 422. PubMed ID: 15871316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants.
    Brin MF; Boodhoo TI; Pogoda JM; James LM; Demos G; Terashima Y; Gu J; Eadie N; Bowen BL
    J Am Acad Dermatol; 2009 Dec; 61(6):961-70.e1-11. PubMed ID: 19744746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of OnabotulinumtoxinA Treatment of Forehead Lines: A Multicenter, Randomized, Dose-Ranging Controlled Trial.
    Solish N; Rivers JK; Humphrey S; Muhn C; Somogyi C; Lei X; Bhogal M; Caulkins C
    Dermatol Surg; 2016 Mar; 42(3):410-9. PubMed ID: 26863598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. OnabotulinumtoxinA (Botox) in the Treatment of Crow's Feet Lines in Japanese Subjects.
    Harii K; Kawashima M; Furuyama N; Lei X; Hopfinger R; Lee E
    Aesthetic Plast Surg; 2017 Oct; 41(5):1186-1197. PubMed ID: 28733805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Rubin M; Dover J; Maas C; Nestor M
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S50-6. PubMed ID: 19945005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study.
    Lowe P; Patnaik R; Lowe N
    J Am Acad Dermatol; 2006 Dec; 55(6):975-80. PubMed ID: 17097394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines.
    Carruthers JD; Lowe NJ; Menter MA; Gibson J; Eadie N;
    Plast Reconstr Surg; 2003 Sep; 112(4):1089-98. PubMed ID: 12973229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.
    Marberger M; Chartier-Kastler E; Egerdie B; Lee KS; Grosse J; Bugarin D; Zhou J; Patel A; Haag-Molkenteller C
    Eur Urol; 2013 Mar; 63(3):496-503. PubMed ID: 23098762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of onabotulinumtoxinA for the treatment of crows feet lines: a multicenter, randomized, controlled trial.
    Carruthers A; Bruce S; de Coninck A; Connolly S; Cox SE; Davis PG; Campo A; Lei X; Somogyi C; Lee E; McLean H; Beddingfield F
    Dermatol Surg; 2014 Nov; 40(11):1181-90. PubMed ID: 25347451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study.
    Magid M; Reichenberg JS; Poth PE; Robertson HT; LaViolette AK; Kruger TH; Wollmer MA
    J Clin Psychiatry; 2014 Aug; 75(8):837-44. PubMed ID: 24910934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.